Protara Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
September 07 2021 - 8:00AM
Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage
company developing transformative therapies for the treatment of
cancer and rare diseases with significant unmet needs, today
announced that management will present at the H.C. Wainwright 23rd
Annual Global Investment Conference being held virtually on
September 13-15, 2021.
The prerecorded presentation will become
available on Monday, September 13, 2021 at 7:00am ET and can be
accessed by visiting the Events and Presentations section of the
Company’s website: https://ir.protaratx.com. The webcast will be
archived on the Company’s website for 90 days following the
presentation.
About Protara Therapeutics, Inc.
Protara is committed to identifying and advancing transformative
therapies for people with cancer and rare diseases with limited
treatment options. Protara’s portfolio includes its lead program,
TARA-002, an investigational cell-based therapy being developed for
the treatment of non-muscle invasive bladder cancer and lymphatic
malformations, and IV Choline Chloride, an investigational
phospholipid substrate replacement therapy for the treatment of
intestinal failure-associated liver disease. For more information,
visit www.protaratx.com.
Company Contact:
Justine O'MalleyProtara
TherapeuticsJustine.OMalley@protaratx.com646-817-2836
Protara Therapeutics (NASDAQ:TARA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Protara Therapeutics (NASDAQ:TARA)
Historical Stock Chart
From Jul 2023 to Jul 2024